Related coverage linked through entity extraction aliases.
Feb 16, 2026
Eli Lilly's Retevmo demonstrated statistically significant improvement in event-free survival versus placebo in stage II-IIIA RET fusion-positive non-small cell lung cancer following curative therapy in the phase 3 LIBRETTO-432 trial.
Feb 16, 2026
Eli Lilly announced positive Phase 3 LIBRETTO-432 trial results showing Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer as adjuvant therapy.
Feb 16, 2026
Eli Lilly committed $1 billion to build an AI-powered supercomputer with Nvidia for drug discovery, launching its TuneLab platform in September and establishing a co-innovation lab by January.
Feb 15, 2026
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
Feb 15, 2026
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025, with successful phase 3 trials for cancer drug Jaypirca, next-gen obesity medicine retatrutide, and oral GLP-1 orforglipron, while Alzheimer's drug Kisunla showed cognitive decline benefits.
Feb 15, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and two additional collaborations totaling over $1 billion to develop treatments for immune disorders, cancer, and hearing loss gene therapies.
Feb 14, 2026
Investigation reveals prescription-only weight-loss drugs Mounjaro and Wegovy are easily accessible in India without proper medical oversight, as semaglutide goes off-patent next month with prices expected to drop 70 percent.
Feb 14, 2026
Novo Nordisk confronts rising generic threats to its semaglutide-based drugs while navigating FDA scrutiny and legal challenges. The company advances oral semaglutide into pediatric diabetes care as competitors prepare to launch imitations.
Feb 14, 2026
Multiple Indian drugmakers begin selling generic versions of Ozempic and Wegovy following March patent expiration, with prices 50-60% below branded counterparts. The launches signal global pricing shifts as Novo Nordisk faces patent losses across multiple markets.
Feb 14, 2026
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
Feb 14, 2026
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Feb 14, 2026
Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial for injectable VK2735 and plans to advance oral VK2735 into Phase 3, while also filing an IND for a new amylin agonist program targeting obesity.
Feb 14, 2026
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Feb 14, 2026
Pharmaceutical companies are deploying AI and machine learning across clinical trial execution, regulatory submissions, and drug discovery to address rising costs and lengthy timelines in drug development.
Feb 13, 2026
Novo Nordisk plans to expand its Athlone facility in Ireland to produce Wegovy for non-US markets and will launch lower-cost vials in the US in 2026, responding to aggressive pricing from Eli Lilly as the company forecasts a 5-13% decline in revenue and operating profit.
Feb 13, 2026
GLP-1 drugs for weight loss and diabetes are driving up health insurance premiums by about 30 percent, while consumer advocates petition for generic authorization citing unjustifiably high prices and strained federal budgets.
Feb 14, 2026
Novo Nordisk launched oral Wegovy in January 2026 with strong early uptake, but faces FDA criticism over misleading advertising and legal battles over compounded alternatives as the company projects sales decline for 2026.
Feb 13, 2026
Viking Therapeutics reported a full-year 2025 net loss of $359.64 million as it rapidly advanced its obesity candidate VK2735 into Phase 3 trials, with both injectable and oral formulations showing double-digit weight loss in earlier studies.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Dec 18, 2025
SCOPE 2026 in Orlando recognized innovation in clinical research with three awards programs, honoring Biogen's lupus webinar series, TrialScreen's site connection initiative, and Biorce's AI platform among 70 competing products.
